A local biotech company has committed to occupying 160,000 square feet on three of the 10 floors under construction at a tower planned to rise at 101 College St. as part of the Downtown Crossing project restitching the center city with the Hill.
The company is called Arvinas. It develops drugs based on targeted protein degradation to treat debilitating and life-threatening diseases like prostate cancer and breast cancer. Incubated at Yale, it has been growing fast.
Winstanley Enterprises plans to begin building 101 College St. in June. Winstanley built the 100 College St. tower across the street on what used to be part of the Route 34 Connector mini-highway to nowhere. The surrounding Downtown Crossing project has a biosciences bent, a bet on the foundations of the city’s economic future.
Arvinas is currently based in Science Park. It plans ot move into the expanded lab and office space at 101 College by 2024 and make it the company headquarters.